Cosmetics Europe Strategizing To Defend Ingredients Flagged As Endocrine Disruptors, CMRs

Clarification of requirements and a “demanding” timeline for industry’s defense of cosmetic ingredients identified as potentially carcinogenic, mutagenic or reprotoxic, and the Commission’s forthcoming list of potential endocrine disruptors in cosmetic products, are among challenges facing Cosmetics Europe in 2019 and beyond.

3d render of Europe map Earth globe

Cosmetics Europe is preparing for challenges amid EU regulatory movement to clamp down on endocrine disruptors while also strategizing to defend CMR (carcinogenic, mutagenic or reprotoxic) substances within what could be a narrow timeframe for industry to build its case.

In a December interview, the trade group’s Director-General John Chave noted that the European Commission’s recent (and long overdue)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By 

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

German Switch Committee Supports OTC Melatonin And Acyclovir, Rejects Rupatadine

 
• By 

Germany’s Expert Committee for Prescription supports the Rx-to-OTC switches of melatonin and buccal acyclovir but rejects rupatadine.

Pharma Deutschland Seeks To Enter Urban Wastewater Legal Dispute

 
• By 

The Urban Wastewater Treatment Directive “in its current form, is at an end,” insists Pharma Deutschland CEO Jörg Wieczorek. To put the directive to bed once and for all, the association has applied for leave to intervene in the ongoing EU legal battle in its own right.

Haleon Invests In State-Of-The-Art Oral Care R&D Facility In The UK

 
• By 

Haleon described the opening of a new oral care R&D facility in the UK as a “major investment reflecting our commitment to advancing science and innovation.”

More from Geography

Viatris Switches Innovative Dual Action Nasal Spray In The UK

 
• By 

Now available without a prescription, Dymista Control is the first OTC combination treatment for consumers who are struggling to control their seasonal allergic rhinitis with a corticosteroid or antihistamine nasal spray, according to the firm.

Haleon Survey Finds Brits Not Paying Enough Attention To Gum Health

 
• By 

Gum health awareness among British consumers could be better, a recent Haleon survey finds.

UK FSA Issues New Guidelines For CBD And THC Max Levels

 
• By 

Based on advice from its advisory committees, the UK's Food Standards Agency is encouraging businesses to meet an acceptable daily intake of 10mg CBD per day and a safe upper limit of 0.07mg THC per day.